Joaquim Gascon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4811016/publications.pdf

Version: 2024-02-01

235 10,804 56
papers citations h-index

89 g-index

269 all docs docs

269 docs citations 269 times ranked 8841 citing authors

#	Article	IF	CITATIONS
1	Chagas disease in Spain, the United States and other non-endemic countries. Acta Tropica, 2010, 115, 22-27.	2.0	496
2	Neurological complications of dengue virus infection. Lancet Neurology, The, 2013, 12, 906-919.	10.2	351
3	Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Tropica, 2007, 103, 195-200.	2.0	338
4	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation, 2018, 138, e169-e209.	1.6	315
5	Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2015, 9, e0003540.	3.0	262
6	Benznidazole and Posaconazole inÂEliminating Parasites in Asymptomatic T.ÂCruzi Carriers. Journal of the American College of Cardiology, 2017, 69, 939-947.	2.8	231
7	Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2018, 18, 419-430.	9.1	214
8	Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 635-639.	3.2	188
9	Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malaria Journal, 2002, $1,1.$	2.3	175
10	<i>Aeromonas</i> spp. and Traveler's Diarrhea: Clinical Features and Antimicrobial Resistance. Emerging Infectious Diseases, 2003, 9, 552-555.	4.3	159
11	Tolerance of Benznidazole in Treatment of Chagas' Disease in Adults. Antimicrobial Agents and Chemotherapy, 2010, 54, 4896-4899.	3.2	152
12	Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators. Journal of Infectious Diseases, 2007, 195, 1089-1096.	4.0	140
13	Chagas disease and stroke. Lancet Neurology, The, 2010, 9, 533-542.	10.2	133
14	Prevalence and Vertical Transmission of <i>Trypanosoma cruzi </i> Infection among Pregnant Latin American Women Attending 2 Maternity Clinics in Barcelona, Spain. Clinical Infectious Diseases, 2009, 48, 1736-1740.	5.8	131
15	Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus Erythematosus. American Journal of Tropical Medicine and Hygiene, 2010, 82, 583-587.	1.4	121
16	Seroprevalence of <i>Trypanosoma cruzi</i> infection in atâ€risk blood donors in Catalonia (Spain). Transfusion, 2008, 48, 1862-1868.	1.6	119
17	Benznidazole-Related Adverse Drug Reactions and Their Relationship to Serum Drug Concentrations in Patients with Chronic Chagas Disease. Antimicrobial Agents and Chemotherapy, 2013, 57, 390-395.	3.2	119
18	Socio-Cultural Aspects of Chagas Disease: A Systematic Review of Qualitative Research. PLoS Neglected Tropical Diseases, 2013, 7, e2410.	3.0	114

#	Article	IF	CITATIONS
19	FAILURE OF STANDARD TREATMENT WITH PRAZIQUANTEL IN TWO RETURNED TRAVELERS WITH SCHISTOSOMA HAEMATOBIUM INFECTION. American Journal of Tropical Medicine and Hygiene, 2006, 74, 342-344.	1.4	114
20	The BENEFIT Trial: Where Do We Go from Here?. PLoS Neglected Tropical Diseases, 2016, 10, e0004343.	3.0	112
21	Allomonal effect of breath contributes to differential attractiveness of humans to the African malaria vector Anopheles gambiae. Malaria Journal, 2004, 3, 1.	2.3	110
22	ETIOLOGY OF DIARRHEA IN CHILDREN YOUNGER THAN 5 YEARS OF AGE ADMITTED IN A RURAL HOSPITAL OF SOUTHERN MOZAMBIQUE. American Journal of Tropical Medicine and Hygiene, 2007, 76, 522-527.	1.4	109
23	Typing and Characterization of Mechanisms of Resistance of Shigella  spp. Isolated from Feces of Children under 5 Years of Age from Ifakara, Tanzania. Journal of Clinical Microbiology, 1999, 37, 3113-3117.	3.9	104
24	New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1129-1140.	9.1	101
25	Human Immunodeficiency Virus Type 1 Infection Is Associated with Significant Mucosal Inflammation Characterized by Increased Expression of CCR5, CXCR4, and βâ€Chemokines. Journal of Infectious Diseases, 2000, 182, 1625-1635.	4.0	99
26	Immunosuppression and Chagas Disease: A Management Challenge. PLoS Neglected Tropical Diseases, 2013, 7, e1965.	3.0	97
27	Sex-specific and blood meal-induced proteins of Anopheles gambiae midguts: analysis by two-dimensional gel electrophoresis. Malaria Journal, 2003, 2, 1.	2.3	96
28	ETIOLOGY OF DIARRHEA IN CHILDREN LESS THAN FIVE YEARS OF AGE IN IFAKARA, TANZANIA. American Journal of Tropical Medicine and Hygiene, 2004, 70, 536-539.	1.4	96
29	Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplantation Reviews, 2011, 25, 91-101.	2.9	95
30	Prevalence of <i>Shigella</i> Enterotoxins 1 and 2 among <i>Shigella</i> Strains Isolated from Patients with Traveler's Diarrhea. Journal of Clinical Microbiology, 1999, 37, 3608-3611.	3.9	95
31	Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: Immigration and Chagas disease in Barcelona (Spain). Acta Tropica, 2009, 111, 51-55.	2.0	94
32	Age as a Risk Factor for Severe Manifestations and Fatal Outcome of Falciparum Malaria in European Patients: Observations from TropNetEurop and SIMPID Surveillance Data. Clinical Infectious Diseases, 2003, 36, 990-995.	5.8	93
33	Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Tropica, 2011, 118, 110-117.	2.0	92
34	Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Review of Anti-Infective Therapy, 2014, 12, 479-496.	4.4	88
35	Health Policies to Control Chagas Disease Transmission in European Countries. PLoS Neglected Tropical Diseases, 2014, 8, e3245.	3.0	86
36	First Description of an Escherichia coli Strain Producing NDM-1 Carbapenemase in Spain. Antimicrobial Agents and Chemotherapy, 2011, 55, 4402-4404.	3.2	85

#	Article	IF	CITATIONS
37	Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. The Lancet Global Health, 2017, 5, e439-e447.	6.3	84
38	Congenital Trypanosoma cruzi infection in a non-endemic area. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1161-1162.	1.8	78
39	EnteroaggregativeEscherichia coliVirulence Factors in Traveler's Diarrhea Strains. Journal of Infectious Diseases, 2000, 182, 1780-1783.	4.0	77
40	Epidemiology, Etiology and Pathophysiology of Traveler's Diarrhea. Digestion, 2006, 73, 102-108.	2.3	77
41	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Review of Anti-Infective Therapy, 2019, 17, 145-157.	4.4	77
42	Congenital transmission of Chagas disease: a clinical approach. Expert Review of Anti-Infective Therapy, 2010, 8, 945-956.	4.4	76
43	Myocardial involvement in Chagas disease: Insights from cardiac magnetic resonance. International Journal of Cardiology, 2013, 165, 107-112.	1.7	75
44	Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates of Plasmodium falciparumin Europe. Journal of Infectious Diseases, 2004, 190, 1541-1546.	4.0	73
45	Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 422-432.	1.6	73
46	Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. GastroenterologÃa Y HepatologÃa, 2010, 33, 191-200.	0.5	71
47	Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. Clinical Microbiology and Infection, 2015, 21, 567.e1-567.e10.	6.0	71
48	Population Pharmacokinetics of Benznidazole in Adult Patients with Chagas Disease. Antimicrobial Agents and Chemotherapy, 2015, 59, 3342-3349.	3.2	66
49	Antimicrobial Resistance of Diarrheagenic <i>Escherichia coli</i> Isolated from Children under the Age of 5 Years from Ifakara, Tanzania. Antimicrobial Agents and Chemotherapy, 1999, 43, 3022-3024.	3.2	63
50	Schistosomiasis of the Male Genital Tract: Transrectal Sonographic Findings. Journal of Urology, 1997, 158, 1491-1493.	0.4	62
51	Quinolone Resistance in Enterotoxigenic <i>Escherichia coli</i> Causing Diarrhea in Travelers to India in Comparison with Other Geographical Areas. Antimicrobial Agents and Chemotherapy, 2000, 44, 1731-1733.	3.2	60
52	Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. Journal of Antimicrobial Chemotherapy, 2009, 64, 343-347.	3.0	58
53	Aetiology of traveller's diarrhoea: evaluation of a multiplex PCR tool to detect different enteropathogens. Clinical Microbiology and Infection, 2014, 20, 0753-0759.	6.0	57
54	Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal, 2017, 16, 57.	2.3	57

#	Article	IF	CITATIONS
55	What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. Journal of Antimicrobial Chemotherapy, 2018, 73, 1060-1067.	3.0	57
56	The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator?. Malaria Journal, 2010, 9, 266.	2.3	54
57	Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2012, 30, 5038-5058.	3.8	54
58	Chagas Cardiomiopathy: The Potential of Diastolic Dysfunction and Brain Natriuretic Peptide in the Early Identification of Cardiac Damage. PLoS Neglected Tropical Diseases, 2010, 4, e826.	3.0	52
59	Guidelines on the Treatment of Chronic Coinfection by <i>Trypanosoma cruzi </i> li>and HIV Outside Endemic Areas. HIV Clinical Trials, 2011, 12, 287-298.	2.0	50
60	Chagas Disease among the Latin American Adult Population Attending in a Primary Care Center in Barcelona, Spain. PLoS Neglected Tropical Diseases, 2011, 5, e1135.	3.0	50
61	Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005501.	3.0	50
62	Imported malaria in a cosmopolitan European city: A mirror image of the world epidemiological situation. Malaria Journal, 2008, 7, 56.	2.3	49
63	Mechanism of Resistance to Several Antimicrobial Agents in Salmonella Clinical Isolates Causing Traveler's Diarrhea. Antimicrobial Agents and Chemotherapy, 2004, 48, 3934-3939.	3.2	46
64	Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. Expert Review of Anti-Infective Therapy, 2013, 11, 957-976.	4.4	46
65	Use of a Short Fragment of the C-Terminal E Gene for Detection and Characterization of Two New Lineages of Dengue Virus 1 in India. Journal of Clinical Microbiology, 2006, 44, 1519-1529.	3.9	45
66	In Vitro Activity of Rifaximin against Enteropathogens Producing Traveler's Diarrhea. Antimicrobial Agents and Chemotherapy, 2001, 45, 643-644.	3.2	43
67	Myocardial Deformation Analysis in Chagas Heart Disease With the Use of Speckle Tracking Echocardiography. Journal of Cardiac Failure, 2011, 17, 1028-1034.	1.7	42
68	Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers. BMC Infectious Diseases, 2011, 11, 206.	2.9	42
69	Comparative, Clinico-Epidemiologic Study of Schistosoma mansoni Infections in Travellers and Immigrants in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 219-223.	2.9	41
70	The importance of the multidisciplinary approach to deal with the new epidemiological scenario of Chagas disease (global health). Acta Tropica, 2015, 151, 16-20.	2.0	41
71	Quinolone resistance among Shigella spp. isolated from travellers returning from India. Clinical Microbiology and Infection, 2008, 14, 279-281.	6.0	40
72	A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform. PLoS Neglected Tropical Diseases, 2017, 11, e0005770.	3.0	40

#	Article	IF	CITATIONS
73	Clinical and epidemiological features of 33 imported Strongyloides stercoralis infections. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 613-616.	1.8	39
74	CTX-M-15–producing EnteroaggregativeEscherichia colias Cause of Travelers' Diarrhea. Emerging Infectious Diseases, 2011, 17, 1950-1953.	4.3	39
75	In silico Design of an Epitope-Based Vaccine Ensemble for Chagas Disease. Frontiers in Immunology, 2019, 10, 2698.	4.8	39
76	Etiology of traveller's diarrhea in Spanish travellers to developing countries. European Journal of Epidemiology, 1993, 9, 217-223.	5.7	38
77	Antimicrobial resistance in Shigella spp. causing traveller's diarrhoea (1995–2010): A retrospective analysis. Travel Medicine and Infectious Disease, 2013, 11, 315-319.	3.0	38
78	Refractory giardiasis in Spanish travellers. Travel Medicine and Infectious Disease, 2013, 11, 126-129.	3.0	38
79	Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1 Clinical Infectious Diseases, 2015, 61, 1441-1444.	5.8	38
80	Susceptibility patterns of enteroaggregative Escherichia coli associated with traveller's diarrhoea: emergence of quinolone resistance. Journal of Medical Microbiology, 2001, 50, 996-1000.	1.8	38
81	Potential use of synthetic α-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease. Organic and Biomolecular Chemistry, 2013, 11, 5579.	2.8	37
82	Molecular diagnostics for Chagas disease: up to date and novel methodologies. Expert Review of Molecular Diagnostics, 2017, 17, 699-710.	3.1	37
83	Histoplasmosis infection in Spanish travelers to Latin America. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 839-841.	2.9	36
84	Diagnosis, Management, and Treatment of Chronic Chagas' Heart Disease in Areas Where Trypanosoma cruzi Infection Is Not Endemic. Revista Espanola De Cardiologia (English Ed), 2007, 60, 285-293.	0.6	36
85	Molecular Surveillance of Circulating Dengue Genotypes Through European Travelers. Journal of Travel Medicine, 2011, 18, 183-190.	3.0	36
86	Prevalence of Different Virulence Factors and Biofilm Production in Enteroaggregative Escherichia coli Isolates Causing Diarrhea in Children in Ifakara (Tanzania). American Journal of Tropical Medicine and Hygiene, 2008, 78, 985-989.	1.4	36
87	Scientific authorships and collaboration network analysis on Chagas disease: papers indexed in PubMed (1940-2009). Revista Do Instituto De Medicina Tropical De Sao Paulo, 2012, 54, 219-228.	1.1	35
88	Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus. Clinical Microbiology and Infection, 2015, 21, 1095.e5-1095.e9.	6.0	35
89	Import of community-associated, methicillin-resistant Staphylococcus aureus to Europe through skin and soft-tissue infection in intercontinental travellers, 2011–2016. Clinical Microbiology and Infection, 2019, 25, 739-746.	6.0	35
90	Trends in antimicrobial resistance in Campylobacter spp. causing traveler's diarrhea. Apmis, 2007, 115, 218-224.	2.0	34

#	Article	IF	CITATIONS
91	Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8+ T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Molecular Immunology, 2012, 52, 289-298.	2.2	34
92	Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. PLoS Neglected Tropical Diseases, 2016, 10, e0004269.	3.0	34
93	Cyclospora in Patients with Traveller's Diarrhea. Scandinavian Journal of Infectious Diseases, 1995, 27, 511-514.	1.5	33
94	In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagnostic Microbiology and Infectious Disease, 2007, 59, 473-475.	1.8	33
95	Persistence of Zika virus in semen 93 days after the onset of symptoms. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 21-23.	0.5	33
96	Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome in a Rural Area of Mozambique. PLoS ONE, 2011, 6, e16946.	2.5	33
97	Cytoadhesion to gC1qR through Plasmodium falciparum Erythrocyte Membrane Protein 1 in Severe Malaria. PLoS Pathogens, 2016, 12, e1006011.	4.7	33
98	Campylobacter jejuni as a Cause of Traveler's Diarrhea: Clinical Features and Antimicrobial Susceptibility. Journal of Travel Medicine, 1998, 5, 23-26.	3.0	32
99	The Use of Quinacrine in Nitroimidazole-resistant Giardia Duodenalis: An Old Drug for an Emerging Problem. Journal of Infectious Diseases, 2017, 215, 946-953.	4.0	32
100	Failure of mebendazole treatment in Giardia lamblia infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83, 647.	1.8	31
101	Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. Journal of Antimicrobial Chemotherapy, 2008, 61, 1016-1019.	3.0	31
102	Prevalence of Chagas disease in the Latin American immigrant population in a primary health centre in Barcelona (Spain). Acta Tropica, 2009, 112, 228-230.	2.0	30
103	Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe. Bulletin of the World Health Organization, 2014, 92, 771-772.	3.3	30
104	Neurocysticercosis and Population Movements: Analysis of 23 Imported Cases in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 382-384.	2.9	29
105	Malaria prophylaxis policy for travellers from Europe to the Indian Subcontinent. Malaria Journal, 2006, 5, 7.	2.3	29
106	Cyclosporiasis: A Point Source Outbreak Acquired in Guatemala: Table 1. Journal of Travel Medicine, 2006, 13, 334-337.	3.0	29
107	Cytokine and Antibody Responses to Plasmodium falciparum in NaÃ-ve Individuals during a First Malaria Episode: Effect of Age and Malaria Exposure. PLoS ONE, 2013, 8, e55756.	2.5	29
108	Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	29

#	Article	IF	CITATIONS
109	Epidemiology of congenital Chagas disease 6 years after implementation of a public health surveillance system, Catalonia, 2010 to 2015. Eurosurveillance, 2019, 24, .	7.0	29
110	Introducing automation to the molecular diagnosis of Trypanosoma cruzi infection: A comparative study of sample treatments, DNA extraction methods and real-time PCR assays. PLoS ONE, 2018, 13, e0195738.	2. 5	28
111	Rapid immunochromatographic tests for the diagnosis of chronic Chagas disease in at-risk populations: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2019, 13, e0007271.	3.0	28
112	Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?. Expert Opinion on Investigational Drugs, 2020, 29, 947-959.	4.1	28
113	Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas. Journal of Medical Virology, 2008, 80, 711-715.	5.0	27
114	First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease. PLoS ONE, 2017, 12, e0188550.	2.5	27
115	Cases of chikungunya virus infection in travellers returning to Spain from Haiti or Dominican Republic, April-June 2014. Eurosurveillance, 2014, 19, 20853.	7.0	27
116	Hypercoagulability biomarkers in Trypanosoma cruzi-infected patients. Thrombosis and Haemostasis, 2011, 106, 617-623.	3.4	26
117	Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. PLoS Neglected Tropical Diseases, 2020, 14, e0008035.	3.0	26
118	Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection. Clinical Microbiology Reviews, 2022, 35, e0015221.	13.6	26
119	Prevalence of the sat Gene among Clinical Isolates of Shigella spp. Causing Travelers' Diarrhea: Geographical and Specific Differences. Journal of Clinical Microbiology, 2002, 40, 1565-1566.	3.9	25
120	High Antibody Responses against Plasmodium falciparum in Immigrants after Extended Periods of Interrupted Exposure to Malaria. PLoS ONE, 2013, 8, e73624.	2.5	25
121	Characterization of Digestive Involvement in Patients with Chronic T. cruzi Infection in Barcelona, Spain. PLoS Neglected Tropical Diseases, 2014, 8, e3105.	3.0	25
122	Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity. Parasites and Vectors, 2020, 13, 299.	2.5	25
123	Benznidazole for the treatment of Chagas disease. Expert Review of Anti-Infective Therapy, 2021, 19, 547-556.	4.4	25
124	Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagnostic Microbiology and Infectious Disease, 2009, 65, 42-48.	1.8	24
125	Cytokine Profiling in Immigrants with Clinical Malaria after Extended Periods of Interrupted Exposure to Plasmodium falciparum. PLoS ONE, 2013, 8, e73360.	2.5	24
126	Severe Imported Malaria in Adults: Retrospective Study of 20 Cases. American Journal of Tropical Medicine and Hygiene, 2009, 81, 595-599.	1.4	23

#	Article	IF	Citations
127	Genotypic Characterization of Enterotoxigenic Escherichia coli Strains Causing Traveler's Diarrhea. Journal of Clinical Microbiology, 2013, 51, 633-635.	3.9	23
128	Yellow Fever–Associated Viscerotropic Disease in Barcelona, Spain. Journal of Travel Medicine, 2008, 15, 202-205.	3.0	22
129	Towards a New Strategy for Diagnosis of Congenital Trypanosoma cruzi Infection. Journal of Clinical Microbiology, 2017, 55, 1396-1407.	3.9	22
130	Identification of HLA-Aâ^—02:01-restricted CTL epitopes in Trypanosoma cruzi heat shock protein-70 recognized by Chagas disease patients. Microbes and Infection, 2011, 13, 1025-1032.	1.9	21
131	A family cluster of giardiasis with variable treatment responses: refractory giardiasis in a family after a trip to India. Clinical Microbiology and Infection, 2014, 20, O135-O138.	6.0	21
132	Analysis of the mechanisms of resistance to several antimicrobial agents in Shigella spp. causing travellers' diarrhoea. Clinical Microbiology and Infection, 2005, 11, 1044-1047.	6.0	20
133	Identification of Trypanosoma cruzi Discrete Typing Units (DTUs) in Latin-American migrants in Barcelona (Spain). Parasitology International, 2017, 66, 83-88.	1.3	20
134	Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 928-931.	1.6	19
135	Extended spectrum \hat{I}^2 -lactamase-producing Escherichia coli faecal carriage in Spanish travellers returning from tropical and subtropical countries. Clinical Microbiology and Infection, 2014, 20, O636-O639.	6.0	19
136	Imported Zika Virus in a European City: How to Prevent Local Transmission?. Frontiers in Microbiology, 2017, 8, 1319.	3.5	19
137	Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malaria Journal, 2003, 2, 17.	2.3	18
138	Imported Acute Histoplasmosis With Rheumatologic Manifestations in Spanish Travelers: Table 1. Journal of Travel Medicine, 2007, 14, 338-342.	3.0	18
139	Use of rapid diagnostic tests (RDTs) for conclusive diagnosis of chronic Chagas disease – field implementation in the Bolivian Chaco region. PLoS Neglected Tropical Diseases, 2019, 13, e0007877.	3.0	18
140	Mebendazole and metronidazole in giardial infections. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 694.	1.8	17
141	Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 434.	1.8	17
142	Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 516-519.	0.5	17
143	Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2020, 14, e0008529.	3.0	17
144	State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165758.	3.8	17

#	Article	IF	CITATIONS
145	High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study. PLoS Neglected Tropical Diseases, 2018, 12, e0006199.	3.0	17
146	Imported malaria among African immigrants: is there still a relationship between developed countries and their ex-colonies?. Malaria Journal, 2009, 8, 111.	2.3	16
147	Cyanobacteria-like Body (CLB) in Travellers with Diarrhea. Scandinavian Journal of Infectious Diseases, 1993, 25, 253-257.	1.5	15
148	Malaria placental infection with massive chronic intervillositis in a gravida 4 woman. Human Pathology, 2001, 32, 1022-1023.	2.0	15
149	A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 77-82.	2.3	15
150	Trypanosoma cruzi-infected Panstrongylus geniculatus and Rhodnius robustus adults invade households in the Tropics of Cochabamba region of Bolivia. Parasites and Vectors, 2016, 9, 158.	2.5	15
151	Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2016, 374, 188-190.	27.0	15
152	Variability in Malaria Prophylaxis Prescribing Across Europe: A Delphi Method Analysis. Journal of Travel Medicine, 2008, 15, 294-301.	3.0	14
153	Fitness and Molecular Mechanisms of Resistance to Rifaximin in In Vitro Selected Escherichia coli Mutants. Microbial Drug Resistance, 2012, 18, 376-379.	2.0	14
154	The need for global collaboration to tackle hidden public health crisis of Chagas disease. Expert Review of Anti-Infective Therapy, 2014, 12, 393-395.	4.4	14
155	Trypanosoma cruzi infection in a Spanish liver transplant recipient. Clinical Microbiology and Infection, 2015, 21, 687.e1-687.e3.	6.0	14
156	The role of red blood cell exchange for severe imported malaria in the artesunate era: a retrospective cohort study in a referral centre. Malaria Journal, 2016, 15, 216.	2.3	14
157	Design of an Epitope-Based Vaccine Ensemble for Animal Trypanosomiasis by Computational Methods. Vaccines, 2020, 8, 130.	4.4	14
158	Cost-effectiveness of different strategies for screening and treatment of Strongyloides stercoralis in migrants from endemic countries to the European Union. BMJ Global Health, 2020, 5, e002321.	4.7	14
159	Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds. International Journal of Molecular Sciences, 2021, 22, 688.	4.1	14
160	New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open, 2021, 11, e052897.	1.9	14
161	Mapping of Chagas disease research: analysis of publications in the period between 1940 and 2009. Revista Da Sociedade Brasileira De Medicina Tropical, 2011, 44, 708-716.	0.9	13
162	Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease. Methods in Molecular Biology, 2019, 1955, 287-308.	0.9	13

#	Article	IF	CITATIONS
163	Development and Evaluation of a Three-Dimensional Printer–Based DNA Extraction Method Coupled to Loop Mediated Isothermal Amplification for Point-of-Care Diagnosis of Congenital Chagas Disease in Endemic Regions. Journal of Molecular Diagnostics, 2021, 23, 389-398.	2.8	13
164	Measles in Travelers: Are We Aware Enough?. Journal of Travel Medicine, 2008, 15, 124-125.	3.0	12
165	Epidemiology of imported malaria among children and young adults in Barcelona (1990-2008). Malaria Journal, 2011, 10, 347.	2.3	12
166	Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditionsâ€. PLoS Neglected Tropical Diseases, 2021, 15, e0009809.	3.0	12
167	Epidemiology and Clinical Presentation of Shigellosis in Children Less Than Five Years of Age in Rural Mozambique. Pediatric Infectious Disease Journal, 2007, 26, 1059-1061.	2.0	11
168	Vaccination Strategies Against Hepatitis A in Travelers Older Than 40 Years: An Economic Evaluation. Journal of Travel Medicine, 2009, 16, 344-348.	3.0	11
169	Characterization of digestive disorders of patients with chronic Chagas disease in Cochabamba, Bolivia. Heliyon, 2019, 5, e01206.	3.2	11
170	Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease. Emerging Infectious Diseases, 2020, 26, 1846-1851.	4.3	11
171	DISSEMINATION OF SALMONELLA ENTERICA SEROTYPE AGONA AND MULTIDRUG-RESISTANT SALMONELLA ENTERICA SEROTYPE TYPHIMURIUM IN CUBA. American Journal of Tropical Medicine and Hygiene, 2006, 74, 1049-1053.	1.4	11
172	CHLOROQUINE AND AMODIAQUINE RESISTANT FALCIPARUM MALARIA IN RWANDA. Lancet, The, 1985, 326, 1072.	13.7	10
173	Magnesium and chronic fatigue syndrome. Lancet, The, 1991, 338, 641.	13.7	10
174	Salmonella ovarian abscess following travel diarrhoea episode. Archives of Gynecology and Obstetrics, 2007, 276, 551-553.	1.7	10
175	Chagas disease: from Latin America to the world. Reports in Parasitology, 0, , 7.	0.5	10
176	Arthritis and Benznidazole: More Closely Related than We Thought. Antimicrobial Agents and Chemotherapy, 2015, 59, 727-729.	3.2	9
177	Enteric fever in Barcelona: Changing patterns of importation and antibiotic resistance. Travel Medicine and Infectious Disease, 2016, 14, 577-582.	3.0	9
178	Zika virus infection in pregnant travellers and impact on childhood neurodevelopment in the first two years of life: A prospective observational study. Travel Medicine and Infectious Disease, 2021, 40, 101985.	3.0	9
179	Genetic diversity of Shigella species from different intercontinental sources. Infection, Genetics and Evolution, 2005, 5, 349-353.	2.3	8
180	Human African Trypanosomiasis in a Spanish traveler returning from Tanzania. PLoS Neglected Tropical Diseases, 2017, 11, e0005324.	3.0	8

#	Article	IF	Citations
181	Co-infection with two emergent old pathogens: Trypanosoma cruzi and Helicobacter pylori. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 751-752.	0.5	7
182	Bolivian migrants with Chagas disease in Barcelona, Spain: a qualitative study of dietary changes and digestive problems. International Health, 2011, 3, 289-294.	2.0	7
183	Chikungunya virus infections among travellers returning to Spain, 2008 to 2014. Eurosurveillance, 2016, 21, .	7.0	7
184	Anti-Trypanosoma cruzi activity of alkaloids isolated from Habranthus brachyandrus (Amaryllidaceae) from Argentina. Phytomedicine, 2022, 101, 154126.	5.3	7
185	The Use of AlphaFold for In Silico Exploration of Drug Targets in the Parasite Trypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 0, 12 , .	3.9	7
186	Changing pattern of malaria in Nyarutovu (Rwanda). Transactions of the Royal Society of Tropical Medicine and Hygiene, 1984, 78, 421-422.	1.8	6
187	Epidemiology of malaria in Nyarutovu (Rwanda): a clinical, parasitological and serological study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 222.	1.8	6
188	Cytomegalovirus and Epstein-Barr Virus Infection as a Cause of Chronic Fatigue Syndrome in Travelers to Tropical Countries. Journal of Travel Medicine, 1995, 2, 41-44.	3.0	6
189	Class 1 Integrons in Salmonella Strains Causing Traveler's Diarrhea. Antimicrobial Agents and Chemotherapy, 2006, 50, 1612-1613.	3.2	6
190	Imported Dengue Hemorrhagic Fever, Europe. Emerging Infectious Diseases, 2008, 14, 1329-1330.	4.3	6
191	Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends - a Delphi method study. Malaria Journal, 2011 , 10 , 137 .	2.3	6
192	Pulmonary Infiltrates and Eosinophilia in a 25-Year-Old Traveler. PLoS Neglected Tropical Diseases, 2013, 7, e2201.	3.0	6
193	Identification of Trypanosoma cruzi Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs. Microorganisms, 2021, 9, 406.	3.6	6
194	Multi-criteria decision analysis approach for strategy scale-up with application to Chagas disease management in Bolivia. PLoS Neglected Tropical Diseases, 2021, 15, e0009249.	3.0	6
195	Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease. Parasites and Vectors, 2021, 14, 337.	2.5	6
196	Serological reactivity against T. cruzi-derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease Acta Tropica, 2021, 221, 105990.	2.0	6
197	A Case of Urogenital Human Schistosomiasis from a Non-endemic Area. PLoS Neglected Tropical Diseases, 2015, 9, e0004053.	3.0	6
198	Rapid Suppression of HIV-RNA Is Associated with Improved Control of Immune Activation in Mozambican Adults Initiating Antiretroviral Therapy with Low CD4 Counts. AIDS Research and Human Retroviruses, 2011, 27, 705-711.	1.1	5

#	Article	IF	CITATIONS
199	Factors associated with risk behavior in travelers to tropical and subtropical regions. International Health, 2015, 7, 272-279.	2.0	5
200	Twenty-four cases of imported zika virus infections diagnosed by molecular methods. Diagnostic Microbiology and Infectious Disease, 2016, 86, 160-162.	1.8	5
201	Differences in tetracycline resistance determinant carriage among Shigella flexneri and Shigella sonnei are not related to different plasmid Inc-type carriage. Journal of Global Antimicrobial Resistance, 2018, 13, 131-134.	2.2	5
202	Leptospirosis in Spanish travelers returning from Chiang Mai: A case series. Travel Medicine and Infectious Disease, 2018, 23, 77-79.	3.0	5
203	Strengthening the Bolivian pharmacovigilance system: New surveillance strategies to improve care for Chagas disease and tuberculosis. PLoS Neglected Tropical Diseases, 2020, 14, e0008370.	3.0	5
204	European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study. Orphanet Journal of Rare Diseases, 2020, 15, 291.	2.7	5
205	Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi. Pharmaceuticals, 2021, 14, 638.	3.8	5
206	Antimicrobial Resistance of NontyphoidalSalmonellalsolates in Traveler's Diarrhea. Journal of Travel Medicine, 1995, 2, 45-47.	3.0	4
207	Characterization of the enzyme aac(3)-id in a clinical isolate of Salmonella enterica serovar Haifa causing traveler's diarrhea. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2009, 27, 453-456.	0.5	4
208	Bordetella pertussis infection among international travellers: The need for a rigorous implementation of vaccine policies. Travel Medicine and Infectious Disease, 2015, 13, 259-260.	3.0	4
209	Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. Journal of Travel Medicine, 2018, 25, .	3.0	4
210	How effective are rapid diagnostic tests for Chagas disease?. Expert Review of Anti-Infective Therapy, 2021, 19, 1489-1494.	4.4	4
211	Probing forÂTrypanosoma cruzi Cell SurfaceÂGlycobiomarkers for the Diagnosis and Follow-Up of Chemotherapy of Chagas Disease. , 2018, , 195-211.		4
212	Computer-Aided Analysis of West Sub-Saharan Africa Snakes Venom towards the Design of Epitope-Based Poly-Specific Antivenoms. Toxins, 2022, 14, 418.	3.4	4
213	MALARIA CHEMOPROPHYLAXIS AND TRAVELLER'S WEIGHT. Lancet, The, 1988, 332, 791-792.	13.7	3
214	Response to `letter to the editor: â€`Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'Â'. Expert Review of Anti-Infective Therapy, 2019, 17, 673-675.	4.4	3
215	Genetic polymorphism of <i>Trypanosoma cruzi</i> bloodstream populations in adult chronic indeterminate Chagas disease patients from the E1224 clinical trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 578-584.	3.0	3
216	Aetiology, epidemiology, and management of traveller's diarrhoea. Reviews in Medical Microbiology, 2003, 14, 73-78.	0.9	2

#	Article	IF	CITATIONS
217	IntoxicaciÃ ³ n por ciguatoxina en viajeros. Medicina ClÃnica, 2003, 120, 777-779.	0.6	2
218	Diagnosis of Trypanosoma cruzi Infection Status using Saliva of Infected Subjects. American Journal of Tropical Medicine and Hygiene, 2018, 98, 464-467.	1.4	2
219	Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network. PLoS Neglected Tropical Diseases, 2022, 16, e0010072.	3.0	2
220	Chloroquine-resistant falciparum malaria from Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986, 80, 351.	1.8	1
221	Endothelial Function and High-Sensitivity C-reactive Protein Levels in Patients With Chagas Disease Living in a Nonendemic Area. Revista Espanola De Cardiologia (English Ed), 2011, 64, 891-896.	0.6	1
222	Host-Derived Molecules as Novel Chagas Disease Biomarkers: Hypercoagulability Markers in Plasma. Methods in Molecular Biology, 2019, 1955, 275-286.	0.9	1
223	Community-based entomological surveillance in three Chagas disease-endemic regions in sub-Andean Bolivia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1251-1259.	1.8	1
224	Challenges in Chagas Disease Control Through Transmission Routes. , 2020, , 37-55.		1
225	Chagas Disease in Europe. Birkhauser Advances in Infectious Diseases, 2019, , 111-123.	0.3	1
226	Entamoeba histolytica and airline personnel. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 700-701.	1.8	0
227	Avian Influenza. Emerging Infectious Diseases, 2009, 15, 1334a-1334.	4.3	0
228	Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 514-517.	0.3	0
229	Blood and Tissue Protozoa. , 2017, , 1751-1762.e1.		0
230	Title is missing!. , 2020, 14, e0008529.		0
231	Title is missing!. , 2020, 14, e0008529.		0
232	Title is missing!. , 2020, 14, e0008529.		0
233	Title is missing!. , 2020, 14, e0008529.		0
234	Title is missing!. , 2020, 14, e0008529.		0

ARTICLE IF CITATIONS
235 Title is missing!., 2020, 14, e0008529. 0